Applied Genetic Technologies Corp. (NASDAQ:AGTC) CFO Lawrence E. Bullock purchased 10,000 shares of the business’s stock in a transaction dated Monday, September 19th. The stock was bought at an average price of $8.75 per share, for a total transaction of $87,500.00. Following the completion of the acquisition, the chief financial officer now directly owns 10,000 shares in the company, valued at approximately $87,500. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Shares of Applied Genetic Technologies Corp. (NASDAQ:AGTC) opened at 8.82 on Wednesday. The firm’s 50-day moving average price is $13.27 and its 200-day moving average price is $14.77. Applied Genetic Technologies Corp. has a 12 month low of $8.50 and a 12 month high of $21.43. The firm’s market cap is $159.23 million.

Applied Genetic Technologies Corp. (NASDAQ:AGTC) last released its quarterly earnings results on Monday, September 12th. The company reported $0.15 EPS for the quarter, topping analysts’ consensus estimates of $0.07 by $0.08. Applied Genetic Technologies Corp. had a negative return on equity of 1.34% and a negative net margin of 2.92%. The company had revenue of $12.10 million for the quarter. During the same quarter last year, the company earned ($0.48) earnings per share. The firm’s revenue for the quarter was up 1604.2% on a year-over-year basis. Analysts expect that Applied Genetic Technologies Corp. will post ($0.61) earnings per share for the current year.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/21/applied-genetic-technologies-corp-agtc-cfo-lawrence-e-bullock-buys-10000-shares.html

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Acadian Asset Management LLC boosted its position in Applied Genetic Technologies Corp. by 234.3% in the first quarter. Acadian Asset Management LLC now owns 296,464 shares of the company’s stock worth $4,145,000 after buying an additional 207,776 shares during the period. BlackRock Fund Advisors boosted its position in Applied Genetic Technologies Corp. by 3.7% in the first quarter. BlackRock Fund Advisors now owns 462,972 shares of the company’s stock worth $6,472,000 after buying an additional 16,541 shares during the period. BlackRock Institutional Trust Company N.A. boosted its position in Applied Genetic Technologies Corp. by 13.8% in the first quarter. BlackRock Institutional Trust Company N.A. now owns 162,328 shares of the company’s stock worth $2,269,000 after buying an additional 19,736 shares during the period. Acrospire Investment Management LLC purchased a new position in Applied Genetic Technologies Corp. during the first quarter worth approximately $197,000. Finally, Spark Investment Management LLC boosted its position in Applied Genetic Technologies Corp. by 22.6% in the first quarter. Spark Investment Management LLC now owns 99,900 shares of the company’s stock worth $1,396,000 after buying an additional 18,400 shares during the period. Institutional investors own 60.10% of the company’s stock.

A number of research analysts have recently issued reports on the company. Cantor Fitzgerald reiterated a “buy” rating and issued a $32.00 price target on shares of Applied Genetic Technologies Corp. in a report on Wednesday, June 22nd. Janney Montgomery Scott cut Applied Genetic Technologies Corp. from a “buy” rating to a “sell” rating and lowered their price objective for the stock from $23.00 to $11.00 in a research report on Tuesday, September 13th. Roth Capital cut Applied Genetic Technologies Corp. from a “buy” rating to a “neutral” rating and lowered their price objective for the stock from $34.00 to $12.00 in a research report on Tuesday, September 13th. Wedbush lowered their price objective on Applied Genetic Technologies Corp. from $36.00 to $20.00 and set an “outperform” rating for the company in a research report on Tuesday, September 13th. Finally, Stifel Nicolaus lowered their price objective on Applied Genetic Technologies Corp. from $29.00 to $24.00 and set a “buy” rating for the company in a research report on Tuesday, September 13th. Two research analysts have rated the stock with a sell rating, four have given a hold rating and four have assigned a buy rating to the company. The stock has an average rating of “Hold” and an average target price of $17.44.

About Applied Genetic Technologies Corp.

Applied Genetic Technologies Corp is a United States-based clinical stage biotechnology company. The Company develops gene therapy products for the treatment of inherited and acquired diseases. Its products are used to treat Alpha One Antitrypsin Deficiency (Alpha-1), a respiratory disease caused by deficiencies in the tissue protective protein alpha one antitrypsin; and Lebers congenital amaurosis, an inherited condition causing early blindness.

5 Day Chart for NASDAQ:AGTC

Receive News & Ratings for Applied Genetic Technologies Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Applied Genetic Technologies Corp. and related companies with MarketBeat.com's FREE daily email newsletter.